Chromophobe renal cell carcinoma (RCC): Oncological outcomes and prognostic factors in a large multicentre series

  • Alessandro Volpe
  • , Giacomo Novara
  • , Alessandro Antonelli
  • , Roberto Bertini
  • , Michele Billia
  • , Giorgio Carmignani
  • , Sergio Cosciani Cunico
  • , Nicola Longo
  • , Guido Martignoni
  • , Andrea Minervini
  • , Vincenzo Mirone
  • , Alchiede Simonato
  • , Carlo Terrone
  • , Filiberto Zattoni
  • , Vincenzo Ficarra
  • , O. De Cobelli
  • , G. Martorana
  • , R. Schiavina
  • , S. Corti
  • , C. Simeone
  • M. Castelli, S. Cimino, V. Favilla, G. Morgia, C. Imbimbo, M. Carini, L. Masieri, S. Serni, F. Oneto, V. Varca, F. Rocco, C. Valotto, E. Costantini, M. Porena, A. Zucchi, S. Ciciliato, N. Lampropoulou, S. Siracusano, D. Fontana, P. Gontero, A. Tizzani, W. Artibani, M. Brunelli, F. Montorsi, G. Petralia, M. Roscigno, E. Strada

Risultato della ricerca: Contributo su rivistaArticolo in rivistapeer review

Abstract

OBJECTIVES: • To investigate cancer-related outcomes of chromophobe renal cell carcinoma (ChRCC) in a large multicentre dataset. • To determine prognostic factors for recurrence-free survival (RFS) and cancer-specific survival (CSS) for this RCC histological type. PATIENTS AND METHODS: • In all, 291 patients with ChRCC were identified from a multi-institutional retrospective database including 5463 patients who were surgically treated for RCC at 16 Italian academic centres between 1995 and 2007. • Univariable and multivariable Cox regression models were used to identify prognostic factors predictive of RFS and CSS after surgery for ChRCC. RESULTS: • At a median follow-up of 44 months, 25 patients (8.6%) had disease recurrence and 18 patients (6.2%) died from disease.• The 5-year RFS and CSS rates were 89.3% and 93%, respectively. • Gender ( P = 0.014), clinical T stage ( P = 0.017), pathological T stage ( P = 0.003), and sarcomatoid differentiation ( P = 0.032) were independent predictors of RFS at multivariable analysis. • For CSS, there was an independent prognostic role for gender ( P = 0.032) and T stage ( P = 0.019) among the clinical variables and for T stage ( P = 0.016), N/M stage ( P = 0.023), and sarcomatoid differentiation ( P = 0.015) among the pathological variables. CONCLUSIONS: • Patients with ChRCC have a low risk of tumour progression, metastasis, and cancer-specific death. • Patient gender, clinical and pathological tumour stage, and sarcomatoid differentiation are significant predictors of RFS and CSS for ChRCC.

Lingua originaleInglese
pagine (da-a)76-83
Numero di pagine8
RivistaBJU International
Volume110
Numero di pubblicazione1
DOI
Stato di pubblicazionePubblicato - lug 2012

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

  1. SDG 3 - Salute e benessere
    SDG 3 Salute e benessere

Fingerprint

Entra nei temi di ricerca di 'Chromophobe renal cell carcinoma (RCC): Oncological outcomes and prognostic factors in a large multicentre series'. Insieme formano una fingerprint unica.

Cita questo